Heart failure (HF) is a significant problem, contributing to one in every eight deaths in the United States, but the risk prediction models currently available for HF remain limited at best.
Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.
New medical treatments such as gene therapies come with a high price tag up to six figures, and drugmakers are working hard to ensure they can get reimbursed for these medicines in creative ways.
Patients can now use AI to monitor their glucose levels with off-the-shelf, noninvasive wearable sensors, according to a new study published in Scientific Reports.
Pharmaceutical company Novartis has partnered with the U.K.’s National Health Service to study inclisiran, an investigational cholesterol-lowering drug that experts project could save 30,000 lives over the next decade.
MyndYou, a New York City-based healthcare technology company, will now be working with Allscripts clients to monitor their patients for cognitive changes and avoid hospitalization whenever possible.
